MedTrace Logo

A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease

NCT02172924 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-11-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.

Conditions

  • Graft vs Host Disease

Interventions

BIOLOGICAL

Early Decidual stromal cell therapy

Intervention given within 7 days after corticosteroids.

BIOLOGICAL

Late Decidual stromal cell therapy

Intervention given after 7 days after corticosteroids.

Sponsors & Collaborators

Principal Investigators

  • Olle Ringdén, MD, PhD · Karolinska Institutet

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172924 on ClinicalTrials.gov